Special Emphasis on the Role of Genetic Make-up

Image

Immunogenetics: Opne Access deals with various aspects of genetic research areas of autoimmune disorders such as multiple sclerosis, rheumatoid arthritis, Crohn’s disease, diabetes mellitus type 1, systemic lupus erythematous, etc. Articles on genetics of cell interaction with immune system, immune response to transplantation, immune based therapies for treatment of cancers, antigenic phylogeny of alleles, alloantigens are also welcome.

Immunogentics: Open Access journal is at higher echelons that enhance the research and information dissemination on topics closely related to Immunology and Genetic Research areas. They provide a unique forum dedicated to scientists to express their research articles, review articles, case reports and short communications on Immuogentics. The Journal supported by universally prominent Editorial Board members.

The Journal Immunogentics: Open Access is mainly based on the number of articles that undergo a double blind peer review process by competent Editorial Board so as to ensure excellence, essence of the work and number of citations received for the same published articles. Our journal is using Editorial Tracking system for online submissions, reviewing the manuscripts. Abstracts and full texts of all articles published by Immunogenetics: Opne Access Journals are freely accessible to everyone immediately after publication.

The Journal is successfully running in the 4th Volume which covers a wide variety of specialties including Multiple sclerosis, Rheumatoid arthritis, Crohn’s disease, diabetes mellitus type 1 reaching out to analytical scientists worldwide. The Journal emphasizes high-level research and education. Original research articles, reviews, short communications, and letters to the editors in the fields of Immunogenetics and Histocompatibility Research are welcome. Every effort is made to have a speedy and critical peer review process.

How we work:

  • After submission, an acknowledgement with manuscript number is sent to the corresponding author within 7 working days.
  • A 21 day window time frame is allotted for peer-review process wherein multiple experts are contacted.
  • Author proof is generated within 7 working days after the acceptance decision.

Benefits on Publication:

Open Access: Permanent free access to your article upon publication ensures extensive global reach and readership.

Global Marketing: Through promotion in a targeted global email announcement or press release, your article will be seen by thousands of the top-most thought-leaders in your field.

 

Media Contact:

Robert Solomon

Managing Editor

Immunogenetics: Open Access

E-mail: immunogenetics@eclinicalsci.com

Whatsapp: +1-504-608-239